SCHEMBL5320862

SCHEMBL5320862

CCCC(c1ccccc1)C(N)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.46
MEN1 O00255 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
KMT2A Q03164 1/20 0.46
AOC3 Q16853 2/20 0.45
SLC1A2 P43004 2/20 0.43
ALOX5 P09917 1/20 0.43
SLC1A3 P43003 1/20 0.43
SLC1A1 P43005 1/20 0.43
ADRA2A P08913 1/20 0.41
ADRA2C P18825 1/20 0.41
LMNA P02545 1/20 0.41
HIF1A Q16665 1/20 0.41
KDM4E B2RXH2 1/20 0.41
GRM2 Q14416 1/20 0.41
GRM3 Q14832 1/20 0.41
SRC P12931 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5289685 0.90 POLB (0.48) CYP2D6MEN1CYP2C9CYP2C19KMT2A
SCHEMBL6533633 0.88 CSNK1E (0.44) CYP2D6MEN1CYP2C9CYP2C19KMT2A
SCHEMBL497439 0.85 CYP2D6 (0.49) CYP2D6MEN1CYP2C9CYP2C19KMT2A
SCHEMBL1162118 0.85 CYP2D6 (0.49) CYP2D6MEN1CYP2C9CYP2C19KMT2A
SCHEMBL22338831 0.85 CYP2D6 (0.49) CYP2D6MEN1CYP2C9CYP2C19KMT2A
SCHEMBL5320088 0.84 TAS1R3 (0.43) CYP2D6MEN1CYP2C9CYP2C19KMT2A
SCHEMBL7653146 0.84 HRH1 (0.50) CYP2D6MEN1CYP2C9CYP2C19KMT2A
Hydrochloric Acid SCHEMBL839858 0.84 CYP2D6 (0.47) CYP2D6MEN1CYP2C9CYP2C19KMT2A
SCHEMBL5322662 0.83 PPARG (0.52) CYP2D6SLC1A2SLC1A3SLC1A1
SCHEMBL5565838 0.82 CYP2D6 (0.46) CYP2D6MEN1CYP2C9CYP2C19KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070258899-A1 Diagnostic and therapeutic agents KARYON-CTT LTD (FI) 2007-11-08 US disclosed
WO-2007113385-A1 DIAGNOSTIC AND THERAPEUTIC AGENTS KARYON-CTT LTD (FI) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070258899-A1 Diagnostic and therapeutic agents YBX1, MLX, TPX2 CYP2D6 3900/4885MEN1 927/4885CYP2C9 4588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.